The outlook of companies tied to flagship drugs like Viagra presents a complex investment scenario . While the initial rise of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the loss of exclusivity in key territories has introduced substantial uncertainty . Investors are now facing the effect of rival medicat